Responding to removal of its Medicare “deemed status,” MD Anderson Cancer Center has submitted a “plan of correction” to the Texas Health and Human Services Commission to demonstrate that it is now in compliance with all federal requirements for participation in the Medicare program.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
